IBT secures platform for pharma grade probiotic to prevent antibiotic resistant hospital acquired infections
Building upon the company's unique expertise in developing pharma grade probiotics, Infant Bacterial Therapeutics AB (IBT) has secured an exclusive global license from the Medical College of Wisconsin (MCW) to a technology platform consisting of genetically modified bacteria. IBT will investigate how to develop a pharma grade probiotic based on this platform that addresses the growing problem of hospital acquired infections, which are responsible for high morbidity and mortality rates.
Antibiotic resistance is rising to dangerous levels across the world, including hospital acquired infections caused by vancomycin-resistant enterococci (VRE). VRE infections have become a serious public health challenge linked with the complexities of antibiotic resistance, resulting in 54,000 cases and 5,000 deaths among hospitalized patients in the United States alone. VRE infections are estimated to cause direct annual U.S. healthcare costs of $539M.
“We are now investigating if, and if so how, we can contribute to the care of these patients in alternate pathways to avoid adding further antibiotic resistance. This new opportunity builds on our current focus on IBP-9414, which remains the same, and leverages the pharma grade probiotic leadership and expertise we have established over the last 10 years. We expect to complete IBP-9414 recruitment with existing capital, and are concurrently exploring this new platform with minimum financial exposure”, says Staffan Strömberg, Chief Executive Officer, IBT.
“Combining MCW’s technology with IBT’s expertise in developing bacterial-based therapies presents a significant opportunity to develop new options for combating hospital acquired infections. This opportunity exemplifies MCW’s commitment to translating our knowledge into innovative patient care and pursuing a healthier world. We are eager to see IBT’s further development of this bacterial technology that was invented by Drs. Nita Salzman, Chris Kristich, and Sushma Kommineni in the departments of Pediatrics and Microbiology & Immunology here at MCW”, says Ann Nattinger, MD, MPH, MACP, Associate for Research at MCW.
For additional information please contact
Staffan Strömberg, Chief Executive Officer
This information is information that Infant Bacterial Therapeutics AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 10:10 CET on January 12, 2023.
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Innofactor Plc: Share Repurchase 4.12.20234.12.2023 17:30:00 CET | Press release
Innofactor Plc Announcement 4.12.2023Innofactor Plc: Share Repurchase 4.12.2023In the Helsinki Stock ExchangeTrade date 4.12.2023Bourse trade BuyShare IFA1VAmount 4,700SharesAverage price/ share 1.1600EURTotal cost 5,452.00EURInnofactor Plc now holds a total of 566 529 sharesincluding the shares repurchased on 4.12.2023On behalf of Innofactor PlcNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information:Sami Ensio, CEOInnofactor PlcTel. +358 50 584 firstname.lastname@example.org Attachment Innofactor_4.12_trades
Borregaard ASA: Share buy-back programme completed4.12.2023 16:58:26 CET | Press release
04.12.2023: Borregaard ASA (”Borregaard”, OSE ticker: BRG) Reference is made to the stock exchange notice of 17 November 2023 where Borregaard announced the intent to repurchase up to 200,000 of its outstanding common stock. The repurchase of shares will be conducted in a period from 20th November up to and including 20th December 2023 at the latest. Borregaard has in the period from 29 November up to and including 4 December in total purchased 60,204 own shares through broker at an average price of NOK 173.24 per share. By these transactions, Borregaard has completed its share buy-back programme by repurchasing 200,000 shares of its outstanding common stock. Aggregated overview of transactions per day: DateAggregated daily volume (number of shares)Weighted average share price per day (NOK)Total daily transaction value (NOK)29.11.20239,142173.32161,584,506.0730.11.202317,258172.80752,982,311.8401.12.202316,902172.73082,919,495.9804.12.202316,902174.14862,943,459.64Previously disclosed
BBS-Bioactive Bone Substitutes Plc: Managers' Transactions - Pekka Jalovaara4.12.2023 15:45:00 CET | Press release
BBS-Bioactive Bone Substitutes Plc, Company announcement, Management transactions, 4 December 2023 at 4.45 p.m. (EET) BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Pekka Jalovaara ____________________________________________ Person subject to the notification requirement Name: Jalovaara Pekka Position: Member of the Board/Deputy member Issuer: BBS Bioactive Bone Substitutes Oyj LEI: 743700BYSBP0PCR6N767 Notification type: INITIAL NOTIFICATION Reference number: 743700BYSBP0PCR6N767_20231203205051_6 ____________________________________________ Transaction date: 2023-11-30 Venue not applicable Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT ISIN: FI4000260583 Nature of the transaction: DISPOSAL Transaction details (1): Volume: 126,606 Unit price: 0.005012 EUR Aggregated transactions (1): Volume: 126,606 Volume weighted average price: 0.005012 EUR ____________________________________________ Person subject to the notification requirement Name: J
AB Linas Agro Group: notification on acquisition of block of shares of the Company4.12.2023 15:21:52 CET | Press release
AB Linas Agro Group, ISIN code LT0000128092 (hereinafter - the Company), received a notification from UAB “SB Asset Management” on the acquisition of block of shares and voting rights of the Company (enclosed). Additional information: Mažvydas Šileika, Finance Director of AB Linas Agro Group Mob. +370 619 19 403 E-mail email@example.com Attachment Notification-of-aquisition-of-block-of-shares LNA-s1204
XPENG G9 secures third place in Car of the Year in Denmark 20244.12.2023 15:04:22 CET | Press release
XPENG G9 secures a top 3 position in The Car of the Year in Denmark Photo credit: Lars Krogsgaard COPENHAGEN, Denmark, Dec. 04, 2023 (GLOBE NEWSWIRE) -- XPENG Motors ("XPENG" or the "Company," NYSE: XPEV and HKEX: 9868), a leading Chinese smart EV company, last week secured third place in Denmark’s Car of the Year 2024 for their flagship SUV, XPENG G9. Denmark’s annual Car of the Year is a tribute to cars that demonstrate outstanding qualities and drive ground-breaking innovations. The award is organised by the association of Danish Motor Journalists. This year, the jury consisted of 20 car experts from a wide range of media. XPENG G9 brings some of the most powerful and advanced EV technology to Europe, including XPENG's latest powertrain system with 800 V Silicon Carbide (SiC) platform for ultra-fast charging of up to 300 kW, allowing drivers to add up to 100 km of range in just five minutes. XPENG G9 had previously proved its worth with an impressive performance during the initial r